Psoriasis Drug's skin gene secrets revealed in small trial

NCT ID NCT01872546

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the drug adalimumab affects gene activity in the skin of people with chronic plaque psoriasis. Researchers compared skin samples from normal, non-lesional, and lesional areas before and after treatment. The goal was to understand the immune changes that happen when the drug works, not to test if it works. Only 18 adults participated, and the study is already completed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Adalimumab

What this could lead to

If successful, this could help doctors understand how adalimumab works in the skin and guide better psoriasis treatments.

What could go wrong

This is a very small, early study (18 people) focused on gene patterns, not on proving the drug works. Results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chu Poitiers

    Poitiers, 86021, France